Clinical Trials Directory

Trials / Sponsors / Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

Industry · 26 registered clinical trials.

StatusTrialPhaseStarted
TerminatedA Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disea
Systemic Sclerosis With and Without Interstitial Lung Disease
Phase 12023-03-10
CompletedStudy of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
Pulmonary Arterial Hypertension
Phase 32022-03-18
CompletedA Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
Hypertension, Pulmonary
Phase 22021-12-29
CompletedA Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZEN
Pulmonary Arterial Hypertension
Phase 32021-12-01
CompletedA Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)
Pulmonary Arterial Hypertension
Phase 32021-01-25
TerminatedExtension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dys
Facioscapulohumeral Muscular Dystrophy, Charcot-Marie-Tooth Disease
Phase 22019-05-10
CompletedA Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Phase 22019-04-19
CompletedA Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial Hypertension
Phase 22018-06-13
CompletedA Study of ACE-2494 in Healthy Subjects
Healthy Volunteers
Phase 12018-02-15
TerminatedStudy of ACE-083 in Patients With Charcot-Marie-Tooth Disease
Charcot-Marie-Tooth Disease
Phase 22017-07-31
TerminatedStudy of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)
Facioscapulohumeral Muscular Dystrophy
Phase 22016-11-01
CompletedExtension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previou
β-Thalassemia
Phase 22014-10-20
CompletedExtension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes
Phase 22014-10-09
CompletedPhase 1 Study of ACE-083 in Healthy Subjects
Musculoskeletal Diseases
Phase 12014-09-01
CompletedStudy of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Advanced Adult Hepatocellular Carcinoma
Phase 1 / Phase 22014-08-04
CompletedStudy to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A53
B-Thalassemia
Phase 22013-02-28
CompletedStudy of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001
Anemia
Phase 22013-01-21
TerminatedStudy of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Phase 22012-12-01
CompletedStudy of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Phase 22011-10-01
CompletedStudy of ACE-536 in Healthy Postmenopausal Women
Anemia
Phase 12011-09-01
TerminatedExtension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Phase 22010-10-01
TerminatedStudy of ACE-031 in Subjects With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Phase 22010-04-01
CompletedStudy of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma
Advanced Solid Tumors, Multiple Myeloma
Phase 12009-10-01
CompletedA Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women
Muscular Atrophy
Phase 12009-08-01
CompletedA Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmeno
Muscle Loss
Phase 12008-09-01
CompletedA Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women
Osteoporosis
Phase 12008-01-01